CN114939104B - 一种用于减轻猫应激的外用透皮制剂、制备方法及应用 - Google Patents
一种用于减轻猫应激的外用透皮制剂、制备方法及应用 Download PDFInfo
- Publication number
- CN114939104B CN114939104B CN202210625978.1A CN202210625978A CN114939104B CN 114939104 B CN114939104 B CN 114939104B CN 202210625978 A CN202210625978 A CN 202210625978A CN 114939104 B CN114939104 B CN 114939104B
- Authority
- CN
- China
- Prior art keywords
- gabapentin
- preparation
- transdermal
- gel
- cat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 48
- 241000282326 Felis catus Species 0.000 title claims abstract description 46
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 claims abstract description 139
- 229960002870 gabapentin Drugs 0.000 claims abstract description 68
- 239000002904 solvent Substances 0.000 claims abstract description 18
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 13
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 13
- 239000003381 stabilizer Substances 0.000 claims abstract description 13
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 claims abstract description 5
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 claims abstract description 5
- 230000000699 topical effect Effects 0.000 claims abstract 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 30
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 21
- 238000003756 stirring Methods 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 14
- 239000008213 purified water Substances 0.000 claims description 14
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 13
- 239000003623 enhancer Substances 0.000 claims description 12
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 12
- 229920000053 polysorbate 80 Polymers 0.000 claims description 12
- 239000003755 preservative agent Substances 0.000 claims description 11
- 230000002335 preservative effect Effects 0.000 claims description 11
- 238000009472 formulation Methods 0.000 claims description 10
- 239000003431 cross linking reagent Substances 0.000 claims description 8
- 229960000686 benzalkonium chloride Drugs 0.000 claims description 6
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims description 6
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 5
- 230000008961 swelling Effects 0.000 claims description 5
- 238000009736 wetting Methods 0.000 claims description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 3
- 229920002125 Sokalan® Polymers 0.000 claims description 3
- 229960001631 carbomer Drugs 0.000 claims description 3
- 238000004090 dissolution Methods 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 2
- WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 claims 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 claims 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 claims 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 claims 1
- 229940082484 carbomer-934 Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 17
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 abstract description 11
- 238000011282 treatment Methods 0.000 abstract description 7
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 abstract description 6
- 229960003639 laurocapram Drugs 0.000 abstract description 6
- 229940079593 drug Drugs 0.000 abstract description 5
- FCGXLCNBWYIEAA-UHFFFAOYSA-N 1,3-benzothiazol-6-ylmethanamine Chemical compound NCC1=CC=C2N=CSC2=C1 FCGXLCNBWYIEAA-UHFFFAOYSA-N 0.000 abstract description 4
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 abstract description 4
- 229940022682 acetone Drugs 0.000 abstract description 4
- RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 abstract description 4
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 abstract description 4
- 230000001624 sedative effect Effects 0.000 abstract description 3
- -1 transdermal promoter Substances 0.000 abstract description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 230000007794 irritation Effects 0.000 abstract 1
- 239000000932 sedative agent Substances 0.000 abstract 1
- 239000000499 gel Substances 0.000 description 27
- 239000000243 solution Substances 0.000 description 13
- 235000006708 antioxidants Nutrition 0.000 description 11
- 230000035882 stress Effects 0.000 description 8
- 208000002193 Pain Diseases 0.000 description 7
- 239000001961 anticonvulsive agent Substances 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 6
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 5
- 229960003965 antiepileptics Drugs 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000003016 pheromone Substances 0.000 description 5
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 5
- 235000010234 sodium benzoate Nutrition 0.000 description 5
- 239000004299 sodium benzoate Substances 0.000 description 5
- 208000019901 Anxiety disease Diseases 0.000 description 4
- 230000036506 anxiety Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 4
- 208000004296 neuralgia Diseases 0.000 description 4
- 208000021722 neuropathic pain Diseases 0.000 description 4
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 3
- JAWPQJDOQPSNIQ-UHFFFAOYSA-N 2-Azaspiro[4.5]decan-3-one Chemical compound C1NC(=O)CC21CCCCC2 JAWPQJDOQPSNIQ-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 239000005711 Benzoic acid Substances 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 3
- BGNXCDMCOKJUMV-UHFFFAOYSA-N Tert-Butylhydroquinone Chemical compound CC(C)(C)C1=CC(O)=CC=C1O BGNXCDMCOKJUMV-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000001773 anti-convulsant effect Effects 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 235000010233 benzoic acid Nutrition 0.000 description 3
- 229960004365 benzoic acid Drugs 0.000 description 3
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 3
- 238000011088 calibration curve Methods 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 235000019629 palatability Nutrition 0.000 description 3
- 239000004250 tert-Butylhydroquinone Substances 0.000 description 3
- 235000019281 tert-butylhydroquinone Nutrition 0.000 description 3
- 239000011732 tocopherol Substances 0.000 description 3
- 229930003799 tocopherol Natural products 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- MRBKEAMVRSLQPH-UHFFFAOYSA-N 3-tert-butyl-4-hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1 MRBKEAMVRSLQPH-UHFFFAOYSA-N 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 208000000094 Chronic Pain Diseases 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000007910 chewable tablet Substances 0.000 description 2
- 229940068682 chewable tablet Drugs 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 230000008451 emotion Effects 0.000 description 2
- 230000014061 fear response Effects 0.000 description 2
- 150000003951 lactams Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 229920001993 poloxamer 188 Polymers 0.000 description 2
- 229940044519 poloxamer 188 Drugs 0.000 description 2
- 229920001992 poloxamer 407 Polymers 0.000 description 2
- 229940044476 poloxamer 407 Drugs 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000003938 response to stress Effects 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 235000010384 tocopherol Nutrition 0.000 description 2
- 229960001295 tocopherol Drugs 0.000 description 2
- 239000012224 working solution Substances 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 206010065390 Inflammatory pain Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 229960002233 benzalkonium bromide Drugs 0.000 description 1
- KHSLHYAUZSPBIU-UHFFFAOYSA-M benzododecinium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 KHSLHYAUZSPBIU-UHFFFAOYSA-M 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000002844 continuous effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 229940072228 neurontin Drugs 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- YGSFNCRAZOCNDJ-UHFFFAOYSA-N propan-2-one Chemical compound CC(C)=O.CC(C)=O YGSFNCRAZOCNDJ-UHFFFAOYSA-N 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000007939 sustained release tablet Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- 238000001946 ultra-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A61K9/0017—Non-human animal skin, e.g. pour-on, spot-on
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Anesthesiology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
原辅料名称 | 占比w/w(%) |
加巴喷丁 | 5.0 |
EDTA-2Na | 0.1 |
改性纤维素 | 1.2 |
甘油 | 3.0 |
吐温-80 | 1.0 |
氢氧化钠 | 0.5 |
月桂氮酮 | 30.0 |
苯甲酸钠 | 0.1 |
二丁基羟基甲苯 | 0.1 |
纯化水 | 59 |
原辅料名称 | 占比w/w(%) |
加巴喷丁 | 12.0 |
EDTA-2Na | 0.3 |
泊罗沙姆188 | 4.0 |
泊罗沙姆407 | 1.0 |
吐温-80 | 1.0 |
氢氧化钠 | 0.5 |
异山梨醇二甲醚 | 20.0 |
丁基羟基茴香醚 | 0.1 |
苯甲酸 | 0.1 |
纯化水 | 61 |
原辅料名称 | 占比w/w(%) |
加巴喷丁 | 10 |
吐温-80 | 0.2 |
纯化水 | 60 |
丁基羟基茴香醚 | 0.1 |
苯甲酸钠 | 0.1 |
EDTA-2NAa | 0.1 |
丙酮 | 10 |
α-吡咯烷酮 | 至100 |
原辅料名称 | 占比w/w(%) |
加巴喷丁 | 5 |
司盘80 | 0.1 |
纯化水 | 40 |
生育酚 | 0.1 |
苯扎氯铵 | 0.05 |
EDTA-2NAa | 0.1 |
月桂氮酮 | 至100 |
原辅料名称 | 占比w/w(%) |
加巴喷丁 | 12 |
吐温-80 | 0.2 |
纯化水 | 60 |
特丁基对苯二酚 | 0.1 |
三氯叔丁醇 | 0.05 |
EDTA-2NAa | 0.1 |
N-甲基吡咯烷酮 | 至100 |
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210625978.1A CN114939104B (zh) | 2022-06-02 | 2022-06-02 | 一种用于减轻猫应激的外用透皮制剂、制备方法及应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210625978.1A CN114939104B (zh) | 2022-06-02 | 2022-06-02 | 一种用于减轻猫应激的外用透皮制剂、制备方法及应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114939104A CN114939104A (zh) | 2022-08-26 |
CN114939104B true CN114939104B (zh) | 2023-10-24 |
Family
ID=82909888
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210625978.1A Active CN114939104B (zh) | 2022-06-02 | 2022-06-02 | 一种用于减轻猫应激的外用透皮制剂、制备方法及应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114939104B (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1813767A (zh) * | 2006-03-06 | 2006-08-09 | 李海涛 | 一种含有植物甾醇的凝胶剂及其制备方法 |
WO2015144825A1 (en) * | 2014-03-27 | 2015-10-01 | Sanovel Ilac Sanayi Ve Ticaret A.S. | Oral liquid pharmaceutical solution of gabapentin |
CN114028350A (zh) * | 2021-11-18 | 2022-02-11 | 华农(肇庆)生物产业技术研究院有限公司 | 一种减轻猫应激组合物及其制备方法 |
CN114028352A (zh) * | 2021-11-30 | 2022-02-11 | 上海汉维生物医药科技有限公司 | 加巴喷丁软咀嚼片制剂及其制备方法和应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUP0700828A2 (en) * | 2007-12-20 | 2010-01-28 | Richter Gedeon Nyrt | Transdermal pharmaceutical compositions containing tolperisone alone and in combination |
US10441544B2 (en) * | 2017-10-10 | 2019-10-15 | Douglas Pharmaceuticals, Ltd. | Extended release pharmaceutical formulation |
CN113940919A (zh) * | 2021-10-22 | 2022-01-18 | 江苏集萃新型药物制剂技术研究所有限公司 | 固体纳米颗粒及其制备方法、透皮贴剂给药系统及其制备方法和作为神经性疾病药剂的应用 |
-
2022
- 2022-06-02 CN CN202210625978.1A patent/CN114939104B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1813767A (zh) * | 2006-03-06 | 2006-08-09 | 李海涛 | 一种含有植物甾醇的凝胶剂及其制备方法 |
WO2015144825A1 (en) * | 2014-03-27 | 2015-10-01 | Sanovel Ilac Sanayi Ve Ticaret A.S. | Oral liquid pharmaceutical solution of gabapentin |
CN114028350A (zh) * | 2021-11-18 | 2022-02-11 | 华农(肇庆)生物产业技术研究院有限公司 | 一种减轻猫应激组合物及其制备方法 |
CN114028352A (zh) * | 2021-11-30 | 2022-02-11 | 上海汉维生物医药科技有限公司 | 加巴喷丁软咀嚼片制剂及其制备方法和应用 |
Non-Patent Citations (6)
Title |
---|
A pilot study of transdermal gabapentin in cats;Jennifer E. Slovak等;《J Vet Intern Med》;1-7 * |
DEVELOPMENT AND EVALUATION OF TOPICAL GABAPENTIN HYDROGEL;Ganesh Prasad Dixit等;《International Journal of Modern Pharmaceutical Research》;第5卷(第5期);8-12 * |
Efficacy of a topical gabapentin gel in a cisplatin paradigm of chemotherapy-induced peripheral neuropathy;Shahid, M.等;《BMC Pharmacol Toxicol 》;第20卷(第51期);1-11 * |
Ganesh Prasad Dixit等.DEVELOPMENT AND EVALUATION OF TOPICAL GABAPENTIN HYDROGEL.《International Journal of Modern Pharmaceutical Research》.2021,第5卷(第5期),8-12. * |
Jennifer E. Slovak等.A pilot study of transdermal gabapentin in cats.《J Vet Intern Med》.2021,1-7. * |
美洛昔康经皮给药系统的设计与药物动力学评价;袁悦;《CNKI 医药卫生科技》;摘要 * |
Also Published As
Publication number | Publication date |
---|---|
CN114939104A (zh) | 2022-08-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6448001B2 (ja) | 液体配合剤 | |
EP1848270B1 (en) | Transmucosal administration of drug compositions for treating and preventing disorders in animals | |
US8309591B2 (en) | Transmucosal veterinary composition comprising detomidine | |
WO2005115386A1 (de) | Flüssige zubereitung für die veterinärmedizin; verfahren zu deren herstellung und deren verwendung | |
US20050032719A1 (en) | Anthelmintic formulations | |
TWI433691B (zh) | 苯并咪唑之非水性組合物 | |
US7582612B2 (en) | Multi-action anthelmintic formulations | |
BG107038A (bg) | Гелен паразитициден състав | |
EP3113774B1 (en) | Compositions of grapiprant and methods for using the same | |
CN114939104B (zh) | 一种用于减轻猫应激的外用透皮制剂、制备方法及应用 | |
BR102013031277A2 (pt) | processo para preparar uma composição anti-helmíntica, composição anti-helmíntica, método de tratamento veterinário e método de tratamento anti-helmíntico | |
KR20090014183A (ko) | 액상 약제학적 제제 | |
JP6120834B2 (ja) | 大環状ラクトンおよびレバミゾールを含む抗寄生生物性組成物、ならびに寄生生物感染の処置方法 | |
PT1646425E (pt) | Composição parasiticida | |
ES2206406T3 (es) | Composiciones veterinarias para el tratamiento de enfermedades parasitarias. | |
US20080249153A1 (en) | Anthelmintic formulations | |
EP3664800B1 (en) | Therapeutic formulations comprising cox-2 inhibitor and uses thereof | |
US20220175707A1 (en) | Pregabalin formulations and use thereof | |
Singh et al. | Comparative Pharmacokinetics of the Orally Administered Sub-Lethal Doses of Miconazole Nitrate in Labeo Rohita | |
CN112972437B (zh) | 一种包含碘硝酚的长效外用制剂及其制备方法和用途 | |
US20230181552A1 (en) | External preparation of imidacloprid, preparation method and use thereof | |
EP4233854A2 (en) | Therapeutic formulations and uses thereof | |
Adil et al. | Toxicity and Adverse Effects of Veterinary Pharmaceuticals in Animals | |
CN117159576A (zh) | 一种驱虫药物制剂及其制备方法 | |
KR20170099911A (ko) | 파라세타몰 주사 제제 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240304 Address after: 313000 East 2nd Floor, Building 2, Phase 2, No. 926 Changhong East Street, Kangqian Street, Deqing County, Huzhou City, Zhejiang Province (self declared) Patentee after: Huzhou Runchong Biotechnology Co.,Ltd. Country or region after: China Address before: Room 3A02-1, Building 3, Phase VI, Information Port, No. 666, Jianshe 2nd Road, Economic and Technological Development Zone, Xiaoshan District, Hangzhou City, Zhejiang Province, 311225 Patentee before: Hangzhou runchong Guimei Biotechnology Co.,Ltd. Country or region before: China |